This article has multiple issues. Please help improve it or discuss these issues on the talk page. (Learn how and when to remove these messages)
|
The European Federation of Pharmaceutical Industries and Associations (EFPIA) is a Brussels-based trade association and lobbying organisation, founded in 1978 and representing the pharmaceutical industry operating in Europe. Through its membership of 36 national associations and 39 leading pharmaceutical companies,[1] the EFPIA represents 1,900 European companies.[2]
European Federation of Pharmaceutical Industries and Associations | |
 | |
| Formation | 1978 |
|---|---|
| Founded at | Brussels, Belgium |
| Purpose | Trade association |
| Location |
|
Region served | Europe |
Membership | 37 national associations, 55 corporate members |
Key people | Nathalie Moll (General Director) Lars Fruergaard Jørgensen (Chairman of the Board) |
Staff (2023) | 60 |
| Website | www |
EFPIA priorities
editEFPIA priorities include speeding up regulatory approval and reimbursement processes for new medicines, creating a strong science base in Europe, joining forces with key stakeholders on political issues concerning health and addressing safety concerns. EFPIA also includes specialised groups like Vaccines Europe[3] who produce approximately 80% of vaccines used worldwide and European Biopharmaceutical Enterprises harness biotechnology to develop approximately one-fifth of new medicines.
Innovative Medicines Initiative
editThe Innovative Medicines Initiative (IMI) is a public-private partnership designed by the European Commission and EFPIA. It is a pan-European collaboration that brings together large biopharmaceutical companies, small- and medium-sized enterprises (SMEs), patient organisations, academia, hospitals and public authorities. The initiative aims to accelerate the discovery and development of better medicines by removing bottlenecks in the drug development process. It focuses on creating better methods and tools to improve and enhance the drug development process, rather than developing specific, new medicines.
Controversy
editFrom 1991 to 1998 Emer Cooke worked for the EFPIA.[4] She became executive director of the European Medicines Agency (EMA), an agency of the European Union (EU) in charge of the evaluation and supervision of medicinal products, in November 2020.[5]
In a session of the Austrian Parliament member of parliament Gerald Hauser on 1 April 2021 publicly criticised a potential conflict of interest, by her allowing the controversial Oxford–AstraZeneca COVID-19 vaccine to be approved, while having worked for the very same industry in the past as a lobbyist of the EFPIA.[6][7]
See also
editReferences
edit- ^ "Board & Working Parties". www.efpia.eu. Retrieved 2023-04-05.
- ^ "Who we are". www.efpia.eu. Retrieved 2022-05-31.
- ^ "Vaccines Europe".
- ^ "WHO | Emer Cooke". www.who.int. Archived from the original on 28 June 2020. Retrieved 15 January 2022.
- ^ "Emer Cooke takes office as head of EMA | European Medicines Agency". 16 November 2020.
- ^ "FPÖ – Hauser: EMA-Direktorin hat ihr ganzes Arbeitsleben mit Lobbying für die Pharmaindustrie verbracht | Freiheitlicher Parlamentsklub - FPÖ, 01.04.2021".
- ^ Archived at Ghostarchive and the Wayback Machine: "Gerald Hauser zeigt Brisantes über die Impfstoffzulassung auf!". YouTube.
External links
edit- Official website of the European Federation of Pharmaceutical Industries and Associations – (EFPIA)
- Innovative Medicines Initiative (IMI)
- Vaccines Europe (VE)
- European Biopharmaceutical Enterprises (EBE) (Archive Link)
- European Federation of Pharmaceutical Industries and Associations on Twitter